RxDoctor Payments Data

Jesse Rockmore, DO

Urology · Blairsville, GANPI 1225532690

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (51.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 64.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $1,716 and has fallen 72.9% since, to $465 in 2025. That places this record below the midpoint for urology clinicians in GA, where the typical reported total is $4,062.

$2,804in general payments, 2019–2025

Across 36 payments — averaging $77.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Procept Biorobotics Corporation$216
  • Coloplast$174
  • Medtronic$153
  • AbbVie$141
  • Tolmar, Inc.$49
  • plus $255 from 9 others

What the payments were for

  • Travel & lodging$1,32447%
  • Food & beverage$1,44452%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,804 in reported general payments places this provider in the 40th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia →

Medicare billing

Part B allowed, 2024
$189,935
Medicare patients
388
Services billed
7,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron26$15,670
MyrbetriqMirabegron29$15,081
CefuroximeCefuroxime Axetil240$1,999
Tamsulosin Hcl192$1,628
Finasteride147$1,385
Trospium Chloride33$1,367
Solifenacin Succinate19$367
Pentoxifylline12$292
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$289
Ciprofloxacin Hcl36$153
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim56$138
Oxybutynin Chloride42$88
Levofloxacin15$67
Tadalafil11$62
Methocarbamol18$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$43$15,67026 claims
Astellas Pharma US IncMyrbetriq$41$15,08129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 369 urology providers in Georgia.

Other urology in Blairsville

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →